Viking Therapeutics: A Speculative Buy [Seeking Alpha]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Seeking Alpha
VKTX's injectable and oral VK2735 both met Phase 2 endpoints, with discontinuation issues in the oral form likely fixable through slower titration and different dosing. Strong cash reserves, committed manufacturing partner, and a diversified pipeline (including VK2809 for MASH) position VKTX for long-term value creation or strategic or financial buyout/going private. Despite volatility and execution risks, VKTX does not need to be best-in-class; even a third-place role in a massive market could yield substantial returns due to its low market cap. Biotech tech stocks are exceedingly risky and only for patient investors who do not lose sight of both the big picture and the critical nuances. Sylphe_7/iStock via Getty Images Overall Thesis In this article, I will explain—using back-of-the-envelope math and plain English—why the stock of Viking Therapeutics, Inc. ( NASDAQ: VKTX ), one of the frontrunners in the GLP-1 weight-loss drug market, may represent a (relatively) de-ris
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 11/5/25 - Form SCHEDULE
- 10/28/25 - Form 4
- 10/28/25 - Form 4
- VKTX's page on the SEC website